The global Gout Therapeutics market size was estimated at USD 2.9 billion in 2021 and is expected to surpass around USD 4.15 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.8% during the forecast period 2022 to 2030.
Gout is an inflammatory arthritic condition caused by the deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues. Gout is a common form of inflammatory arthritis that is quite painful. It usually affects one joint at a time (often the big toe joint). There are times when symptoms get worse, known as flares, and times when there are no symptoms, known as remission.
Gout is a common and complex form of arthritis that can affect anyone. It is characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in one or more joints, most often in the big toe. It usually occurs earlier in men than women. It generally occurs after menopause in women. Men can be three times more likely than women to get it because they have higher levels of uric acid most of their lives. Women reach these uric acid levels after menopause.
Gout treatment exist; however, therapy should be tailored for each person. Treatment choices depend on kidney function, other health issues, personal preferences, and other factors. Patients could need medications to lower their elevated blood uric acid levels that predispose to gout. Over time, increased uric acid levels in the blood could lead to deposits of urate crystals in and around the joints. These crystals can attract white blood cells, leading to severe, painful gout attacks and chronic arthritis.
Report Scope of the Gout Therapeutics Market
Report Coverage |
Details |
Market Size |
USD 4.15 Billion by 2030 |
Growth Rate |
CAGR of 8.8% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Drug Type, Distribution Channel and Region, |
Companies Mentioned |
|
Increase in Incidence of Gout Propelling Global Gout Therapeutics Market
Gout is the most common type of inflammatory arthropathy. According to several studies, its prevalence and incidence have increased in the last few decades. Hyperuricemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use, and chronic renal disease are the risk factors for the development of gout.
Several studies have shown that gout management in primary care is suboptimal, which could contribute to rise in prevalence of clinically significant symptomatic gout. Obesity, diabetes, and hypertension were found to be common in gout patients in the U.K. and Germany. Age is also a risk factor; hence, population aging is likely to increase the incidence of gout. Complex cases of gout, particularly secondary gout, are becoming more common in hospital practice, with the rising prevalence of advanced chronic kidney disease and usage of diuretics and nephrotoxic drugs potentially driving the global gout therapeutics market size.
Gout incidence and prevalence increases with age, with prevalence reaching 11% to 13% and incidence reaching 0.9% in people over the age of 80. Gout is more common in racial minorities in the U.S., New Zealand Mori, Han Chinese, and some ethnic groups in Asia Pacific.
Rise in Need to Reduce Inflammation and Pain in Joints Augmenting Nonsteroidal Anti?inflammatory Drugs (NSAIDs) Segment
In terms of drug type, the nonsteroidal anti?inflammatory drugs (NSAIDs) segment accounted for the largest gout therapeutic market share in 2021. NSAIDs are aspirin-like medications that can reduce inflammation and pain in joints and other tissues. NSAIDs, such as indomethacin (Indocin) and naproxen (Naprosyn), have become the treatment of choice for the majority of acute gout attacks. There is no evidence that one NSAID is superior to another. High doses of short-acting NSAIDs provide the quickest symptom relief. These medications could cause stomach upset, ulcers, or diarrhea; however, most people tolerate them well when used for a short period of time.
Urate-lowering drugs are utilized for the symptomatic treatment of gout arthritis, as a first line of therapy or in combination therapy. According to estimates, more than 2 million people in the U.S. take medication to decrease serum uric acid levels. Moreover, higher penetration of urate-lowering drugs compared to biologics into the gout therapeutics market for the treatment of people suffering from chronic or acute gout diseases propels the antihyperuricemic agents (urate-lowering drugs) segment.
Increase in Geriatric Population with Moderate to Severe Gout Arthritis Propelling Hospital Pharmacies Segment
Based on distribution channel, the hospital pharmacies segment is projected to account for a dominant share of the global gout therapeutic market in 2021. The segment is anticipated to grow considerably from 2022 to 2031. Hospital pharmacies is expected to be the second-leading segment, in terms of market share, during the forecast period. The segment's large market share is attributed to the increase in geriatric population with moderate to severe gout arthritis requiring hospital pharmacy to purchase drugs.
The online pharmacies segment is likely to grow at a rapid pace during the forecast period. Increase in the number of online pharmacies and acceptance of several gout therapeutics as over-the-counter drugs in medical therapy to penetrate the pharmaceutical and the health care market are projected to augment the online pharmacies segment.
Regional Outlook of Global Gout Therapeutics Market
North America accounted for the largest share of the global gout therapeutics market in 2021. The region is projected to be a highly lucrative market during the forecast period, with high market attractiveness index. Increasing incidence of gout and rising burden of comorbidities in the U.S. are likely to propel the market in the region during the forecast period. Gout is the most common inflammatory arthritis in the country. Several studies have shown an increase in prevalence in the last few decades. There are more than nine million gout patients, and nearly a third of those patients are treated with oral urate-lowering therapies in the past 20 years. The number of people living with gout-related disability has risen steeply in the past few years.
The market in Asia Pacific is expected to grow at a rapid pace from 2022 to 2030. The incidence and prevalence of gout have been steadily increasing in the region, which has resulted in increased research & development activities in gout diagnosis and gout treatment.
Analysis of Key Players in Global Gout Therapeutics Market
The global gout therapeutics market is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global gout therapeutics market. Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Novartis AG, Mylan N.V., MERCK & Co. Inc., Iroko Pharmaceutical LLC, Hikma Pharmaceuticals plc, Horizon Therapeutics plc, and Teva Pharmaceutical Industries Ltd. are the prominent players operating in the global gout therapeutics market.
Key Developments in Global Gout Therapeutics Market
Some of the prominent players in the Gout Therapeutics Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Gout Therapeutics market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders